2-(hexyloxy)isoindoline-1,3-dione | 56076-96-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(hexyloxy)isoindoline-1,3-dione
• 英文别名: 2-hexoxyisoindole-1,3-dione
• CAS: 56076-96-1
• 化学式: C₁₄H₁₇NO₃
• 分子量: 247.294
• InChiKey: VNEXAHNNMMMMON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(hexyloxy)isoindoline-1,3-dione 在 肼 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以97%的产率得到O-1-hexylhydroxylamine hydrochloride
  参考文献：
  名称：

  High; Prior; Bell, Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 288, # 2, p. 490 - 501

  摘要：

  DOI：
• 作为产物：
  描述：

  N-羟基邻苯二甲酰亚胺 、 溴己烷 在 sodium hydride 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 20.5h， 以5.82 g的产率得到2-(hexyloxy)isoindoline-1,3-dione
  参考文献：
  名称：

  PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA

  摘要：

  提供了用于骨髓瘤的新型治疗药物。一种用于多发性骨髓瘤的治疗剂，包含由式（1）表示的吡唑烷化合物：其中R1是C1-C6烷基，C1-C6烷基取代为R17，C1-C6卤代烷基，苯基，苯基取代为R11或类似物，R2是氢原子，C1-C6烷基，苯基或可选地取代为e个R21或类似物，R3是氢原子或类似物，X是单键或—（CR6，R7)n—，R4和R5分别独立地是C1-C6烷基或类似物，R6和R7是氢原子或C1-C6烷基，R8是苯基，苯基可选地取代为k个R81或类似物，所述化合物的互变异构体或其药用上可接受的盐或溶剂，作为活性成分。

  公开号：

  US20130253204A1

文献信息

• Method for producing hematopoietic stem cells using pyrazole compounds
  申请人：Nishino Taito

  公开号：US09212348B2

  公开（公告）日：2015-12-15

  An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R8 are as defined in the description).

  提供一种用于治疗各种造血系统疾病的造血干细胞和/或造血祖细胞的扩增剂，并用于提高基因转移效率以进行基因治疗。提供一种生产造血干细胞和/或造血祖细胞的方法，包括通过在存在以下式(I)所代表的化合物的情况下将造血干细胞在体外培养来扩增造血干细胞，该化合物的互变异构体或药用盐或其溶剂（其中R1至R8如描述中所定义）。
• PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA
  申请人：Nishino Taito

  公开号：US20130253204A1

  公开（公告）日：2013-09-26

  Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R 1 is C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted with R 17 , C 1 -C 6 haloalkyl, phenyl, phenyl substituted with a R 11 's or the like, R 2 is a hydrogen atom, C 1 -C 6 alkyl, phenyl or phenyl optionally substituted with e R 21 's or the like, R 3 is a hydrogen atom or the like, X is a single bond or —(CR 6 , R 7 ) n —, each of R 4 and R 5 is independently C 1 -C 6 alkyl or the like, R 6 and R 7 are hydrogen atoms or C 1 -C 6 alkyl, R 8 is phenyl, phenyl optionally substituted with k R 81 's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

  提供了用于骨髓瘤的新型治疗药物。一种用于多发性骨髓瘤的治疗剂，包含由式（1）表示的吡唑烷化合物：其中R1是C1-C6烷基，C1-C6烷基取代为R17，C1-C6卤代烷基，苯基，苯基取代为R11或类似物，R2是氢原子，C1-C6烷基，苯基或可选地取代为e个R21或类似物，R3是氢原子或类似物，X是单键或—（CR6，R7)n—，R4和R5分别独立地是C1-C6烷基或类似物，R6和R7是氢原子或C1-C6烷基，R8是苯基，苯基可选地取代为k个R81或类似物，所述化合物的互变异构体或其药用上可接受的盐或溶剂，作为活性成分。
• Pyrazole compounds having therapeutic effect on multiple myeloma
  申请人：Nishino Taito

  公开号：US08658686B2

  公开（公告）日：2014-02-25

  Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R1 is C1-C6 alkyl, C1-C6 alkyl substituted with R17, C1-C6 haloalkyl, phenyl, phenyl substituted with a R11's or the like, R2 is a hydrogen atom, C1-C6 alkyl, phenyl or phenyl optionally substituted with e R21's or the like, R3 is a hydrogen atom or the like, X is a single bond or —(CR6R7)n—, each of R4 and R5 is independently C1-C6 alkyl or the like, R6 and R7 are hydrogen atoms or C1-C6 alkyl, R8 is phenyl, phenyl optionally substituted with k R81's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

  提供了治疗骨髓瘤的新型治疗剂。一种多发性骨髓瘤治疗剂，包含由式（1）表示的吡唑化合物，其中R1是C1-C6烷基，C1-C6烷基取代R17，C1-C6卤代烷基，苯基，苯基取代R11或类似基团，R2是氢原子，C1-C6烷基，苯基或苯基可选择地取代e个R21或类似基团，R3是氢原子或类似基团，X是单键或—（CR6R7)n—，R4和R5中的每一个独立地是C1-C6烷基或类似基团，R6和R7是氢原子或C1-C6烷基，R8是苯基，苯基可选择地取代k个R81或类似基团，该化合物的互变异构体或其药学上可接受的盐或溶剂，作为活性成分。
• METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUNDS
  申请人：Asai Ayako

  公开号：US20140057353A1

  公开（公告）日：2014-02-27

  An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R 1 to R 8 are as defined in the description).

  提供一种用于治疗各种造血系统疾病的造血干细胞和/或造血祖细胞扩增剂，并可用于提高基因治疗中基因转移效率的方法。一种生产造血干细胞和/或造血祖细胞的方法，包括在化合物公式（I）所表示的化合物、其互变异构体或药学上可接受的盐或其溶剂的存在下，在体外培养造血干细胞以扩增造血干细胞。其中R1至R8的定义如说明书中所示。
• RAPID DISCOVERY AND SCREENING OF ENZYME ACTIVITY USING MASS SPECTROMETRY
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20150330992A1

  公开（公告）日：2015-11-19

  Described herein are methods, systems, and compositions for detecting enzyme activity. In some embodiments, the reaction product(s) are coupled with a mass tag, and the enzyme activity is determiner by analyzing the reaction product(s). The enzyme assays can be performed using mass spectrometry, for example nanostructure-initiator mass spectrometry (NIMS). Also described are methods, systems, and compositions for monitoring enzymatic degradation process of a substrate sample, for example a biomass.

  本文描述了检测酶活性的方法、系统和组合物。在某些实施例中，反应产物与质量标记偶联，通过分析反应产物来确定酶活性。酶测定可以使用质谱技术进行，例如纳米结构启动子质谱（NIMS）。还描述了监测底物样品（例如生物质）的酶降解过程的方法、系统和组合物。